The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study
| dc.authorid | 0000-0002-0596-8200 | |
| dc.authorid | 0000-0002-0832-382X | |
| dc.authorid | 0000-0003-2787-8828 | |
| dc.authorid | 0000-0001-5435-7898 | |
| dc.authorid | 0000-0001-9354-3570 | |
| dc.authorid | 0000-0003-2444-4784 | |
| dc.authorid | 0000-0003-2679-7460 | |
| dc.contributor.author | Khadhouri, Sinan | |
| dc.contributor.author | Gallagher, Kevin M. | |
| dc.contributor.author | MacKenzie, Kenneth R. | |
| dc.contributor.author | Shah, Taimur T. | |
| dc.contributor.author | Gao, Chuanyu | |
| dc.contributor.author | Moore, Sacha | |
| dc.contributor.author | Zimmermann, Eleanor F. | |
| dc.date.accessioned | 2025-05-10T19:39:43Z | |
| dc.date.issued | 2021 | |
| dc.department | İstanbul Medeniyet Üniversitesi | |
| dc.description.abstract | Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. Patients and Methods This was an international multicentre prospective observational study. We included patients aged >= 16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15; P < 0.001), male sex 1.30 (95% CI 1.14-1.50; P < 0.001), and smoking 2.70 (95% CI 2.30-3.18; P < 0.001). Conclusions A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer. | |
| dc.description.sponsorship | UK National Institute for Health Research (NIHR); UK NIHR Postdoctoral Fellowship; NIHR Birmingham Biomedical Research Centre | |
| dc.description.sponsorship | We would like to thank all of the BURST research collaborators for taking part in this study and Jonathan Deeks for his support from the Test Evaluation Research Group. Veeru Kasivisvanathan is an Academic Clinical Lecturer funded by the UK National Institute for Health Research (NIHR). Yemisi Takwoingi is funded by a UK NIHR Postdoctoral Fellowship and supported by the NIHR Birmingham Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR or the Department of Health and Social Care. Although unrelated to the present study, the BURST research collaborative would like to acknowledge funding from the BJU International, BAUS, Ferring Pharmaceuticals Ltd, and Dominvs Group. | |
| dc.identifier.doi | 10.1111/bju.15483 | |
| dc.identifier.endpage | 450 | |
| dc.identifier.issn | 1464-4096 | |
| dc.identifier.issn | 1464-410X | |
| dc.identifier.issue | 4 | |
| dc.identifier.pmid | 33991045 | |
| dc.identifier.scopus | 2-s2.0-85115243675 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 440 | |
| dc.identifier.uri | https://doi.org/10.1111/bju.15483 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14730/9771 | |
| dc.identifier.volume | 128 | |
| dc.identifier.wos | WOS:000693631300001 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Wiley | |
| dc.relation.ispartof | Bju International | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20250302 | |
| dc.subject | haematuria | |
| dc.subject | bladder cancer | |
| dc.subject | upper tract urothelial cancer | |
| dc.subject | renal cancer | |
| dc.subject | cancer prevalence | |
| dc.subject | hematuria | |
| dc.subject | urinary tract cancer | |
| dc.subject | prostate cancer | |
| dc.title | The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study | |
| dc.type | Article |
Dosyalar
Orijinal paket
1 - 1 / 1










